Treatment of Pleural Amyloidosis
Treatment of amyloid identified in pleural biopsy is determined entirely by the amyloid subtype—AL amyloidosis requires immediate chemotherapy targeting the clonal plasma cell disorder, whereas ATTR amyloidosis requires transthyretin stabilizer therapy (tafamidis) for cardiac involvement or supportive care for isolated pleural disease. 1, 2
Step 1: Mandatory Amyloid Typing
Mass spectrometry (LC-MS/MS) of the pleural biopsy specimen is the gold standard for identifying the precursor protein, with 88% sensitivity and 96% specificity. 1, 2
If mass spectrometry is unavailable, transfer the Congo-red-positive pleural tissue to an experienced reference laboratory for definitive typing—immunohistochemistry alone is insufficient. 2
Never assume AL amyloidosis based solely on the presence of a monoclonal protein; over 10% of patients with monoclonal gammopathy actually have ATTR deposits, and both subtypes can coexist. 1, 2, 3
Step 2: Comprehensive Monoclonal Protein Assessment (Mandatory for All Cases)
Simultaneously obtain serum free light chain assay with κ/λ ratio, serum immunofixation electrophoresis, and urine immunofixation electrophoresis—this combination achieves >99% sensitivity for detecting AL amyloidosis. 4, 1
Bone marrow biopsy demonstrates clonal plasma cells in 69% of AL amyloidosis cases and helps exclude multiple myeloma. 4, 1
If any monoclonal protein is detected (including MGUS), you cannot distinguish AL from ATTR by imaging alone—tissue typing is mandatory. 4, 1, 2
Step 3: Systematic Organ Involvement Assessment
Perform echocardiography, NT-proBNP, troponin, 24-hour urine protein collection, complete metabolic panel, and neurologic examination in all patients to identify cardiac, renal, hepatic, and neurologic involvement—this determines prognosis and treatment intensity. 1, 2
Cardiac involvement is the primary determinant of survival in AL amyloidosis, with approximately 30% of patients dying within the first year if advanced cardiac disease is present. 4
NT-proBNP >5000 ng/L or troponin T >0.06 ng/mL indicates high transplant-related mortality and affects eligibility for autologous stem cell transplant. 4
Step 4: Treatment Based on Amyloid Type
For AL (Light Chain) Amyloidosis
First-line therapy is daratumumab, bortezomib, cyclophosphamide, and dexamethasone (Dara-VCD), which achieves up to 90% hematologic response rates. 4, 5
Autologous stem cell transplant (ASCT) is indicated for transplant-eligible patients (troponin T ≤0.06 ng/mL, NT-proBNP ≤5000 ng/L), achieving median overall survival of 7.6 years and potential cure in complete responders. 4
For non-transplant candidates, bortezomib-based regimens (BMDex or VCD) or melphalan/dexamethasone (MDex) achieve hematologic response rates of 76–90%, with 7-year overall survival of 7.3 years in complete responders. 4
The goal of therapy is at least a very good partial response (VGPR); patients failing to achieve this depth require consolidation with pomalidomide, venetoclax, or bendamustine. 5
Immediate hematology-oncology referral is mandatory to initiate chemotherapy before end-stage organ failure develops. 2, 5
For ATTR (Transthyretin) Amyloidosis
Perform TTR gene sequencing to differentiate wild-type (ATTRwt) from hereditary (ATTRv) disease—this determines eligibility for specific therapies and triggers family screening. 4, 1, 2
For patients with ATTR cardiac amyloidosis and NYHA class I–III heart failure symptoms, tafamidis (VYNDAQEL/VYNDAMAX) is FDA-approved and indicated to reduce cardiovascular mortality and hospitalization. 4, 6
Patisiran (ONPATTRO) is FDA-approved for polyneuropathy of hereditary ATTR amyloidosis in adults but not for isolated cardiac or pleural involvement. 7
For isolated pleural ATTR amyloidosis without cardiac or neurologic involvement, supportive care with diuretics for pleural effusions is the mainstay—there is no specific therapy for pleural-only disease. 4
Step 5: Supportive Management
Diuretics are the mainstay of heart failure therapy in cardiac amyloidosis; avoid ACE inhibitors, ARBs, and β-blockers due to risk of symptomatic hypotension. 4, 2
Never use digoxin or calcium channel blockers—these drugs bind to amyloid fibrils, causing toxicity and exaggerated hypotensive responses even at therapeutic levels. 8
Anticoagulation is recommended for atrial fibrillation regardless of CHA₂DS₂-VASc score due to high thromboembolic risk. 4
Critical Pitfalls to Avoid
Do not delay treatment while awaiting complete organ assessment—initiate chemotherapy for AL amyloidosis immediately after diagnosis to prevent irreversible organ damage. 4, 5
Do not assume the amyloid type based on clinical presentation alone—pleural involvement can occur in both AL and ATTR, and tissue typing is mandatory. 2, 9
Do not treat based on monoclonal protein presence without tissue typing—ATTR and AL can coexist in the same patient, requiring dual therapy. 2, 3
Do not use fat pad biopsy to assess treatment response—it has poor sensitivity for ATTR (15% for wild-type) and does not reflect pleural disease burden. 1, 2